Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 2, 2004 - Issue 6
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Medicine or surgery for myocardial infarction: could facilitated angioplasty offer the best of both worlds?

Simon DR Thackray Castle Hill Hospital, Department of Cardiology, Cottingham, Kingston-upon-Hull, UK. [email protected]
&
M Farqad Alamgir Castle Hill Hospital, Department of Cardiology, Cottingham, Kingston-upon-Hull, UK. [email protected]
Pages 793-797 | Published online: 10 Jan 2014

References

  • Morrison C, Woodward M, Leslie W, Tunstall-Pedoe H. Effect of socioeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. MONICA Project, Royal Infirmary, Glasgow. Br. Med. 1. 314, 541–546 (1997).
  • Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Cardiovascular Epidemiology Unit (MONICA Quality Control Center for Event Registration), University of Dundee, Ninewells Hospital and Medical School, UK. Lancet 353(9164), 1547–1557 (1999).
  • Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2, 10-year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br. Med. 316 (7141), 1337–1343 (1998).
  • French JK, Hyde TA, Patel H et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at 3 to 4 weeks. J Am. Coll. Cardial. 34(1), 62–69 (1999).
  • AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancetl (8585), 545–549 (1988).
  • ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339(8796), 753–770 (1992).
  • Hudson MP, Granger CB, Topol EJ et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 104(11), 1229–1235 (2001).
  • Anderson RD, White HD, Ohman EM et al. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 mm: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. Am. Heart J. 144(1), 81–88 (2002).
  • Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 361(9351), 13–20 (2003).
  • Ross AM, Coyne KS, Moreyra E et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 97(16), 1549–1556 (1998).
  • The ASsessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT-2) investigators. Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet354, 716–722 (1998).
  • Kent DM, Lau J, Selker HP. Balancing the benefits of primary angioplasty against the benefits of thrombolytic therapy for acute myocardial infarction: the importance of timing. Elf Clin. Pract. 4 (5), 214–220 (2001).
  • Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am. J. Cardial. 92 (7), 824–826 (2003).
  • Magid DJ, Calonge BN, Runsfeld JS et al., for the National Registry of Myocardial Infarction 2 and 3 Investigators. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs. thrombolytic therapy. J. Am. Med. Assoc. 284, 3131–3138 (2003).
  • Steg PG, Bonnefoy E, Chabaud S et al. Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 108(23), 2851–2856 (2003).
  • Zijlstra F, Hoorntje JCA, de Boer M-J et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl. J Med. 19 (341), 1413–1419 (1999).
  • Le May MR, Davies RF, Labinaz M et al. Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT study. Circulation 108,2624–2630 (2003).
  • Askari AT, Lincoff AM. GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies To Open occluded coronary arteries. Cleve. Clin. J. Med. 69(7), 554–560 (2003).
  • Antman EM, Giugliano RP, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99 (21), 2720–2732 (1999).
  • Herrmann HC, Moliterno DJ, Ohman EM et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J. Am. Coll. CardioL 36(5), 1489–1496 (2000).
  • Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein Hb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am. Coll. Cardial. 34(5), 1420–1426 (1999).
  • Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein Hb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98(24), 2695–2701 (1998).
  • The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein inhibition: the GUSTO V randomized trial. Lancet 357,1905–1914 (2001).
  • Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 108(15), 1809–1814 (2003).
  • Moon JC, Kalra PR, Coats AJ. DANAMI-2: is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive center? Int. J Cardial. 85(2–3), 199–201 (2002).
  • Antman EM, Giugliano RP, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99 (21), 2720–2732 (1999).
  • Kastrati A, Mehilli J, Schlotterbeck K et al. Bavarian Reperfusion AlternatiVes Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. j Am. Med. Assoc. 291(8), 947–954 (2004).
  • Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction. J. Am. Med. Assoc. 283,2686-2692 pooy
  • Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: 5-year results of the Grampian Region Early Anistreplase Trial (GREAT). J. Am. Coll. Cardial. 30(5), 1181–1186 (1997).
  • Landers EJ, Schut A, Hooghoudt TE et al. Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study. Am. Heart J. 146(3), 479–483 (2003).
  • Pedley DK, Bissett K, Connolly EM et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. Br. Med.1. 327, 22–26 (2003).

Websites

  • National statistics website www.statistics.gov.uk/STATBASE/xsdata set. asp?More=Y 8,zylnk=7175 &A11=Y&B2 .x=49&B2.y=10 (Accessed October 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.